Pharmacological reports : PR · 2020
Favipiravir use for SARS CoV-2 infection.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boretti Alberto
Аннотация
INTRODUCTION: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored.
OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted.
METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent.
RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage.
CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted.
METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent.
RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage.
CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.